Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study

被引:189
|
作者
Fang, Margaret C.
Go, Alan S.
Hylek, Elaine M.
Chang, Yuchiao
Henault, Lori E.
Jensvold, Nancy G.
Singer, Daniel E.
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Kaiser Permanente No Calif, Div Res, Oakland, CA USA
[3] Boston Univ, Sch Med, Gen Internal Med & Clin Epidemiol Unit, Boston, MA 02215 USA
[4] Massachusetts Gen Hosp, Clin Epidemiol Unit, Boston, MA 02114 USA
关键词
aging; anticoagulation; hemorrhage; atrial fibrillation;
D O I
10.1111/j.1532-5415.2006.00828.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To assess whether older age is independently associated with hemorrhage risk in patients with atrial fibrillation, whether or not they are taking warfarin therapy. DESIGN: Cohort study. SETTING: Integrated healthcare delivery system. PARTICIPANTS: Thirteen thousand five hundred fifty-nine adults with nonvalvular atrial fibrillation. MEASUREMENTS: Patient data were collected from automated clinical and administrative databases using previously validated search algorithms. Medical charts were reviewed from patients hospitalized were for major hemorrhage (intracranial, fatal, requiring >= 2 units of transfused blood, or involving a critical anatomic site). Age was categorized into four categories (< 60, 60-69, 70-79, and >= 80), and multivariable Poisson regression was used to assess whether major hemorrhage rates increased with age, stratified by warfarin use and adjusted for other clinical risk factors for hemorrhage. RESULTS: A total of 170 major hemorrhages were identified during 15,300 person-years of warfarin therapy and 162 major hemorrhages during 15,530 person-years off warfarin therapy. Hemorrhage rates rose with older age, with an average increase in hemorrhage rate of 1.2 (95% confidence interval (CI) 1.0-1.4) per older age category in patients taking warfarin and 1.5 (95% CI = 1.3-1.8) in those not taking warfarin. Intracranial hemorrhage rates were significantly higher in those aged 80 and older (adjusted rate ratio = 1.8, 95% CI = 1.1-3.1 for those taking warfarin, adjusted rate ratio = 4.7, 95% Cl = 2.4-9.2 for those not taking warfarin) than in those younger than 80. CONCLUSION: Older age increases the risk of major hemorrhage, particularly intracranial hemorrhage, in patients with atrial fibrillation, whether or not they are taking warfarin. Hemorrhage rates were generally comparable with those reported in previous randomized trials, indicating that carefully monitored warfarin therapy can be used with reasonable safety in older patients.
引用
收藏
页码:1231 / 1236
页数:6
相关论文
共 50 条
  • [21] Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
    Dallalzadeh, Liane O.
    Go, Alan S.
    Chang, Yuchiao
    Borowsky, Leila H.
    Fang, Margaret C.
    Singer, Daniel E.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (07):
  • [22] Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation - The anticoagulation and risk factors in atrial fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Phillips, KA
    Borowsky, LH
    Henault, LE
    Chang, YC
    Selby, JV
    Singer, DE
    CIRCULATION, 2000, 102 (01) : 11 - 13
  • [23] Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage
    Claassen, Daniel O.
    Kazemi, Noojan
    Zubkov, Alexander Y.
    Wijdicks, Eelco F. M.
    Rabinstein, Alejandro A.
    ARCHIVES OF NEUROLOGY, 2008, 65 (10) : 1313 - 1318
  • [24] Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage No
    Schulman, Sam
    STROKE, 2011, 42 (12) : 3663 - 3664
  • [25] Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location
    Ma, Minmin
    Meretoja, Atte
    Churilov, Leonid
    Sharma, Gagan J.
    Christensen, Soren
    Liu, Xinfeng
    Weir, Louise
    Davis, Stephen M.
    Yan, Bernard
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 332 (1-2) : 75 - 79
  • [26] Influence of Competing Risks on the Association Between Warfarin and Ischemic Stroke in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
    Ashburner, Jeffrey M.
    Go, Alan S.
    Chang, Yuchiao
    Fang, Margaret C.
    Fredman, Lisa
    Applebaum, Katie M.
    Singer, Daniel E.
    CIRCULATION, 2015, 132
  • [27] Reinitiation of Anticoagulation After Warfarin-Associated Intracranial Hemorrhage and Mortality Risk: The Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) Study
    Yung, Derek
    Kapral, Moira K.
    Asllani, Eriola
    Fang, Jiming
    Lee, Douglas S.
    CANADIAN JOURNAL OF CARDIOLOGY, 2012, 28 (01) : 33 - 39
  • [28] Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage
    Shendre, Aditi
    Parmar, Gaurav M.
    Dillon, Chrisly
    Beasley, Timothy Mark
    Limdi, Nita A.
    PHARMACOTHERAPY, 2018, 38 (06): : 588 - 596
  • [29] The impact of anticoagulation intensity on severity of stroke in atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Hylek, EM
    Go, AS
    Chang, YC
    Phillips, KA
    Henault, LE
    Capra, AM
    Jensvold, NG
    Selby, JV
    Singer, DE
    CIRCULATION, 2002, 106 (19) : 577 - 578
  • [30] Warfarin therapy in patients with atrial fibrillation: risk of intracranial hemorrhage
    Nature Clinical Practice Cardiovascular Medicine, 2005, 2 (1): : 6 - 6